

## **Global Gene Editing Technology Business and Investment Opportunities - Analysis and Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q2 2023 Update**

Market Report | 2023-08-10 | 1300 pages | BioIntel360

### **AVAILABLE LICENSES:**

- Single User Price \$8900.00
- Multi User Price \$9900.00
- Enterprise User Price \$11900.00

### **Report description:**

Insights and data in the report has been segmented under the following six modules:

#### **Module 1: Global Gene Editing Funding and Investments Outlook**

This module provides insights and data related to gene editing partnerships and investment (research and development, mergers and acquisitions, product development, commercialization, licensing, and manufacturing) and allows a peek into the futuristic trends of gene editing technology investment area.

#### **Module 2: Global Gene Editing Clinical Trial Data Assessment**

This module evaluates the data available from clinical trials conducted for various CRISPR, ZFNs, TALENs, and meganucleases-based therapies, representing a bird's eye view of emerging market dynamics and risks in the gene editing sector.

#### **Module 3: Global Gene Editing Patent Data Analysis**

This module presents an exhaustive study of gene editing patent analytics (CRISPR, ZFN, TALENs, and meganucleases) at various levels, including strategic research planning as well as analyzing their potential applications.

#### **Module 4: Competitive Landscape**

This module provides detailed information along with a scoring matrix of key companies related to the gene editing industry, including their historical performance and the latest developments.

#### **Module 5: Global Gene Editing Market Size and Forecast**

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

This module provides projections on the market's development during the years 2018-2027 after the profound evaluation of market dynamics at the deeper segmentation level. This report also provides an in-depth, data-centric analysis of the global gene editing market at regional and country levels:

#### By Technology

- CRISPR CAS 9
- TALENs
- ZFN
- Others (Meganucleases)

#### By Products

- Kits & Enzymes (By CRISPR, TALENs, ZFN, Meganucleases)
- Cell lines & Antibodies (By CRISPR, TALENs, ZFN, Meganucleases)
- Plasmid & Controls (By CRISPR, TALENs, ZFN, Meganucleases)

#### By Delivery Method

- Ex-vivo
- In-vivo

#### By Disease/Disorders

- Cancer
- Blood Disorders (beta-thalassemia and sickle cell disease)
- Blindness
- Respiratory Disease (COVID-19 & Cystic fibrosis)
- Others (AIDS, Huntington's disease, Muscular dystrophy)

#### By Application

- Drug Development
- Diagnostics
- Plant Gene Editing
- Others (Animal Gene Editing)

#### By End-User

- Pharmaceutical and Biopharmaceutical Companies
- Biotechnology Companies
- Contract Research Organisations
- Academic Institutes and Research Centres

#### By Regions

- North America
  - U. S
  - Canada
  - Mexico
- Europe
  - France
  - United Kingdom

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- Germany
- Italy
- Switzerland

- Asia-Pacific
- China
- Japan
- Australia
- India
- South Korea

- MEA region
- Israel
- South Africa
- Turkey
- U.A. E
- Saudi Arabia

- Latin America
- Brazil
- Argentina

#### Key Companies Covered

- bluebird bio
- Beam Therapeutics
- Caribou Biosciences
- Cellectis
- Allogene Therapeutics
- Intellia Therapeutics
- Editas Medicine
- Verve Therapeutics
- AstraZeneca
- Merck KGaA
- Thermo Fisher Scientific

#### Module 6 Regulatory Outlook

This module contains a detailed understanding of the ethical, legal, and social implications of gene editing technology.

#### **Table of Contents:**

This market intelligence report features an in-depth analysis on the current market dynamics of gene editing technologies such as CRISPR/Cas9, ZFNs, TALENs, and Meganucleases.

It provides a detailed analysis of gene editing market dynamics, covering clinical trials, patent data, financial deals, and competitive landscape through 40+ sections, 1091 tables, and 1467 charts.

Chapter: 1 About this Report

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.1 Research Methodology
- 1.2 Definitions
- 1.3 Disclaimer

## Chapter: 2 Gene Editing Market Dynamics

- 2.1 Introduction
- 2.2 Global Gene Editing Technology Market Outlook and Future Growth Dynamics
  - 2.2.1 Market Opportunities and Growth Dynamics
  - 2.2.2 Strategy and Innovations
  - 2.2.3 Regulation and Challenges Related to Gene Editing Around the Globe
- 2.3 Regulatory Dynamics Assessment Across Different regions
  - 2.3.1 North America Gene Editing Regulations
  - 2.3.2 Europe Gene Editing Regulations
  - 2.3.3 Asia Pacific Gene Editing Regulations
  - 2.3.4 Middle East & Africa region Gene Editing Regulation
  - 2.3.5 Latin America Gene Editing Regulations

## Chapter: 3 Global Gene Editing Technology Discovery and Clinical Pipeline Market Attractiveness

- 3.1 CRISPR Based: Discovery and Clinical Pipeline
- 3.2 TALEN Based: Discovery and Clinical Pipeline
- 3.3 ZFNs Based: Discovery and Clinical Pipeline
- 3.4 Meganucleases Based: Discovery and Clinical Pipeline

## Chapter: 4 Gene Editing Technology Financial Deals & Alliances: Analysis of Emerging Market Dynamics & Outlook, 2018-2027

- 4.1 Gene Editing Technology Financial Deals Market Size and Forecast, 2018-2027
- 4.2 Gene Editing Technology Financial Deals Vs Mergers & Acquisition, 2021 vs 2024
- 4.3 Gene Editing Technology Financial Deals Analysis by Application, 2021 vs 2024
- 4.4 Gene Editing Technology Financial Deals Analysis by Diseases, 2021 vs 2024
- 4.5 Gene Editing Technology Financial Deals Analysis by Region, 2021 vs 2024
- 4.6 Gene Editing Financial Deals Analysis by Type of Technology, 2021 vs 2024
- 4.7 Gene Editing Technology Financial Deals Analysis by End-Use Sector, 2021 vs 2024
- 4.8 Gene Editing Technology Financial Deals by Fundings and Investment
  - 4.8.1 Gene Editing Technology Funding and Investment Annual Analysis, 2018-2027
  - 4.8.2 Gene Editing Technology Funding and Investment by Year, Growth Rate (%)
  - 4.8.3 Gene Editing Technology Funding Analysis by Geographical Regions
  - 4.8.4 Gene Editing Technology: Funding Analysis by Type of Industry Players
  - 4.8.5 Gene Editing Technology: Funding Analysis by Therapeutics
  - 4.8.6 Gene Editing Technology Type of Funding Analysis
- 4.9 Key Financial Deals & Alliances - Recent List of Major Acquisition and Mergers
- 4.10 North America Region Financial Deals
- 4.11 Europe Region Financial Deals

## Chapter: 5 Gene Editing Technology Patent Analysis & Outlook

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.1 Gene Editing Technology Patent Analysis & Outlook, 2018-2027
- 5.2 Gene Editing Technology: Patent Players Overview
- 5.3 Gene Editing Technology: White Space Mapping Analysis
- 5.4 Gene Editing Technology: Keyword Search Expressions
- 5.5 Gene Editing Technology: Type of Innovation Analysis
- 5.6 Gene Editing Technology: Type of Innovation Futuristic Analysis
- 5.7 Gene Editing Technology: CRISPR Top Patent Owners Benchmarking Analysis
- 5.8 Gene Editing Technology: TALENs Top Patent Owners Benchmarking Analysis
- 5.9 Gene Editing Technology: ZFNs Top Patent Owners Benchmarking Analysis
- 5.10 Gene Editing Technology: Patent Valuation Analysis
- 5.11 Gene Editing Technology: Scope of Innovation Analysis
- 5.12 Gene Editing Technology Scope of Innovation FTO Analysis
- 5.13 Trends Associated with Legal Status: Gene Editing Technology
- 5.14 Patent Filing Velocity Analysis: Gene Editing Technology
- 5.15 Trends Associated with Investors: Gene Editing Technology
- 5.16 Trends Associated with Top Applicants: Gene Editing Technology
- 5.17 CPC Code Classification Analysis of Patents by Type of Gene Editing Technology
- 5.18 Geographical Distribution of Patents by Type of Gene Editing Technology
- 5.19 Key Recent Patents by Gene Editing Technology

#### Chapter: 6 Clinical Trial Analysis & Outlook, 2017-2027

- 6.1 Global Gene Editing Technology: Clinical Trial Region-wise Prediction & Estimation, 2018-2027
- 6.2 Clinical Trial Analysis by Key Countries
- 6.3 Clinical Trial Analysis by Disease / Disorder
- 6.4 Gene Editing Technology Clinical Trial Phase-wise Analysis
- 6.5 Gene Editing Technology Clinical Trial Status Analysis
- 6.6 Gene Editing Technology Clinical Trial Study-type Analysis
- 6.7 Snapshot of Key Clinical Trials

#### Chapter: 7 Gene Editing Technology Competitive Landscape Analysis: Key Company Profiles and Strategic Initiatives

- 7.1 Gene Editing Competitive Index Ranking & Attractiveness Quadrant
- 7.2 Gene Editing Technology: Competitive Analysis Quadrant
- 7.3 Gene Editing Competitive Landscape by End Markets
- 7.4 Key Companies by Regions
- 7.5 Competitive Landscape by Type of Gene Editing Technology
- 7.6 Company Profiling
- 7.7 CRISPR Therapeutics AG
- 7.8 bluebird bio
- 7.9 Beam Therapeutics
- 7.10 Caribou Biosciences
- 7.11 Celectis
- 7.12 Allogene Therapeutics
- 7.13 Intellia Therapeutics Inc.
- 7.14 Editas Medicine

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.15 Verve Therapeutics
- 7.16 AstraZeneca
- 7.17 Merck KGaA
- 7.18 Thermo Fisher Scientific Inc.

## Chapter: 8 Gene Editing Technology Market Size and Forecast, 2018-2027

### 8.1 Gene Editing Technology Market Share by Technology (%), 2018-2027

- 8.1.1 Gene Editing Technology Market Size and Forecast by CRISPR, 2018-2027
- 8.1.2 Gene Editing Technology Market Size and Forecast by TALENs, 2018-2027
- 8.1.3 Gene Editing Technology Market Size and Forecast by ZFNs, 2018-2027
- 8.1.4 Gene Editing Technology Market Size and Forecast by Meganucleases, 2018-2027

### 8.2 Gene Editing Technology Market Share by CRISPR Product (%), 2018-2027

- 8.2.1 Gene Editing Technology Market Size and Forecast by Vector Based Cas9, 2018-2027
- 8.2.2 Gene Editing Technology Market Size and Forecast by DNA Free Cas9, 2018-2027
- 8.2.3 Gene Editing Technology Market Size and Forecast by Libraries & Antibodies, 2018-2027
- 8.2.4 Gene Editing Technology Market Size and Forecast by gRNA Design and Vector Construction, 2018-2027
- 8.2.5 Gene Editing Technology Market Size and Forecast by Cell Lines & Engineering, 2018-2027
- 8.2.6 Gene Editing Technology Market Size and Forecast by Others (Plasmid, Controls), 2018-2027

### 8.3 Gene Editing Technology Market Share by TALENs Product (%), 2018-2027

- 8.3.1 Gene Editing Technology Market Size and Forecast by Kits & Enzymes, 2018-2027
- 8.3.2 Gene Editing Technology Market Size and Forecast by Cell lines & Antibodies, 2018-2027
- 8.3.3 Gene Editing Technology Market Size and Forecast by Others (Plasmid, Controls), 2018-2027

### 8.4 Gene Editing Technology Market Share by ZFNs Product (%), 2018-2027

- 8.4.1 Gene Editing Technology Market Size and Forecast by Kits & Enzymes, 2018-2027
- 8.4.2 Gene Editing Technology Market Size and Forecast by Cell lines & Antibodies, 2018-2027
- 8.4.3 Gene Editing Technology Market Size and Forecast by Others (Plasmid, Controls), 2018-2027

### 8.5 Gene Editing Technology Market Share by Meganucleases Product (%), 2018-2027

- 8.5.1 Gene Editing Technology Market Size and Forecast by Kits & Enzymes, 2018-2027
- 8.5.2 Gene Editing Technology Market Size and Forecast by Cell lines & Antibodies, 2018-2027
- 8.5.3 Gene Editing Technology Market Size and Forecast by Others (Plasmid, Controls), 2018-2027

### 8.6 Gene Editing Technology Market Share by Delivery Mode (%), 2018-2027

- 8.6.1 Gene Editing Technology Market Size and Forecast by Ex-vivo, 2018-2027
- 8.6.2 Gene Editing Technology Market Size and Forecast by In-vivo, 2018-2027

### 8.7 Gene Editing Technology Market Share by Disease/Disorders (%), 2018-2027

- 8.7.1 Gene Editing Technology Market Size and Forecast by Cancer, 2018-2027
- 8.7.2 Gene Editing Technology Market Size and Forecast by Blood Disorders, 2018-2027
- 8.7.3 Gene Editing Technology Market Size and Forecast by Blindness, 2018-2027
- 8.7.4 Gene Editing Technology Market Size and Forecast by Respiratory Disease, 2018-2027
- 8.7.5 Gene Editing Technology Market Size and Forecast by Others, 2018-2027

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

8.8 Gene Editing Technology Market Share by Application (%), 2018-2027

8.8.1 Gene Editing Technology Market Size and Forecast by Drug Development, 2018-2027

8.8.2 Gene Editing Technology Market Size and Forecast by Diagnostics, 2018-2027

8.8.3 Gene Editing Technology Market Size and Forecast by Plant Gene Editing, 2018-2027

8.8.4 Gene Editing Technology Market Size and Forecast by Animal Gene Editing, 2018-2027

8.9 Gene Editing Technology Market Share by End User (%), 2018-2027

8.9.1 Gene Editing Technology Market Size and Forecast by Pharmaceutical and Biopharmaceutical Companies, 2018-2027

8.9.2 Gene Editing Technology Market Size and Forecast by Biotechnology Companies, 2018-2027

8.9.3 Gene Editing Technology Market Size and Forecast by Contract Research Organisations, 2018-2027

8.9.4 Gene Editing Technology Market Size and Forecast by Academic Institutes and Research Centres, 2018-2027

Chapter 9- Chapter 39: This section contains chapters providing gene editing market sizing and forecast for additional 21 countries and 6 regions.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Global Gene Editing Technology Business and Investment Opportunities - Analysis and Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q2 2023 Update**

Market Report | 2023-08-10 | 1300 pages | BioIntel360

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User Price	\$8900.00
	Multi User Price	\$9900.00
	Enterprise User Price	\$11900.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-03"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

An empty rectangular box with a thin black border, intended for a signature.